Hélène Haegel

Trained as an immunologist, Hélène started working on adenovirus-based gene therapies at Transgene
SA in 1999. In 2003, she shifted her research toward cancer immunotherapy and supported the
preclinical development of therapeutic antibodies. She joined Roche in 2018 to work on the
immunological safety of T cell engagers. Since 2019 she is back in the field of gene therapy, working on
the immunology of AAV-based gene therapies with a focus on immunogenicity assessment and
mitigation.